Ritedose Pharmaceuticals Launches Cromolyn Sodium Oral Solution (Concentrate) 100 mg/5 ml

COLUMBIA, S.C. (January 5, 2022) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product, Cromolyn Sodium Oral Solution (Concentrate), 100 mg/5 ml. The oral solution is the first of a new product line for Ritedose Pharmaceuticals which has historically offered a portfolio of generic inhalation solutions. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies, research development programs, hospitals, wholesalers and pharmacies.

“We’re pleased to expand our generics portfolio,” said Ritedose President and CEO Jody Chastain. “With a broad array of products currently in development and launching soon, we’ll be able to offer our clients even more of the many products they regularly need with ample, reliable supplies.”

Founded in 1995 in Columbia, South Carolina, The Ritedose Corporation is an industry leader in the aseptic manufacturing and packaging of single-dose medication, and utilizes proven Blow-Fill-Seal (BFS) equipment and processes to ensure efficient, consistent and safe dosage delivery. The company’s 25-year track record includes delivery of more than 8 billion doses since 2012 without a single recall, and its current capacity is 2.1 billion units annually.

To request more information on Ritedose products or to place an order or contact us.

Pioneers in aseptic production of sterile, single-dose medication